{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:35:59Z","timestamp":1792035359131,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000632","name":"Healthcare Infection Society","doi-asserted-by":"publisher","award":["Travel grant"],"award-info":[{"award-number":["Travel grant"]}],"id":[{"id":"10.13039\/501100000632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000672","name":"Pathological Society of Great Britain and Ireland","doi-asserted-by":"publisher","award":["Travel grant"],"award-info":[{"award-number":["Travel grant"]}],"id":[{"id":"10.13039\/501100000672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10096-019-03679-9","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T11:02:51Z","timestamp":1567854171000},"page":"2311-2321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis"],"prefix":"10.1007","volume":"38","author":[{"given":"J. W. S.","family":"Cattrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"As\u00edn-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. F.","family":"Troc\u00f3niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2440-9316","authenticated-orcid":false,"given":"A.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"issue":"3","key":"3679_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/519268","volume":"45","author":"CA Czaja","year":"2007","unstructured":"Czaja CA, Scholes D, Hooton TM, Stamm WE (2007) Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 45(3):273\u2013280. \nhttps:\/\/doi.org\/10.1086\/519268","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3679_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):103\u2013120. \nhttps:\/\/doi.org\/10.1093\/cid\/ciq257","journal-title":"Clin Infect Dis"},{"key":"3679_CR3","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters (v 6.0). \nhttp:\/\/www.eucast.org\/"},{"issue":"5","key":"3679_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","volume":"21","author":"E As\u00edn-Prieto","year":"2015","unstructured":"As\u00edn-Prieto E, Rodr\u00edguez-Gasc\u00f3n A, Isla A (2015) Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents. J Infect Chemother 21(5):319\u2013329. \nhttps:\/\/doi.org\/10.1016\/j.jiac.2015.02.001","journal-title":"J Infect Chemother"},{"issue":"2","key":"3679_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2008","unstructured":"Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61(2):235\u2013237. \nhttps:\/\/doi.org\/10.1093\/jac\/dkm476","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3679_CR6","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/jac\/dkw226","volume":"71","author":"F De Velde","year":"2016","unstructured":"De Velde F, de Winter BCM, Koch BCP, van Gelder T, Mouton JW (2016) Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. J Antimicrob Chemother 71(10):2909\u20132917. \nhttps:\/\/doi.org\/10.1093\/jac\/dkw226","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3679_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jps.2600670217","volume":"67","author":"DS Greene","year":"1978","unstructured":"Greene DS, Quintiliani R, Nightingale CH (1978) Physiological perfusion model for cephalosporin antibiotics I: model selection based on blood drug concentrations. J Pharm Sci 67(2):191\u2013196. \nhttps:\/\/doi.org\/10.1002\/jps.2600670217","journal-title":"J Pharm Sci"},{"issue":"6","key":"3679_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ijantimicag.2008.05.019","volume":"32","author":"J-M Conil","year":"2008","unstructured":"Conil J-M, Georges B, de Lussy A, Khachman D, Seguin T, Ruiz S et al (2008) Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents 32(6):505\u2013510. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2008.05.019","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"3679_CR9","doi-asserted-by":"publisher","first-page":"6472","DOI":"10.1128\/AAC.01321-15","volume":"59","author":"SL Parker","year":"2015","unstructured":"Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D et al (2015) Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother 59(10):6472\u20136476. \nhttps:\/\/doi.org\/10.1128\/AAC.01321-15","journal-title":"Antimicrob Agents Chemother"},{"key":"3679_CR10","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-tenth edition: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (2015) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-tenth edition: approved standard. NCCLS, Wayne"},{"key":"3679_CR11","unstructured":"RStudio Team (2015) RStudio: Integrated Development Environment for R. Boston, MA, USA"},{"key":"3679_CR12","unstructured":"Lavielle M. mlxR: Simulation of longitudinal data. \nhttps:\/\/CRAN.R-project.org\/package=mlxR"},{"key":"3679_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2: Elegant graphics for data analysis","author":"H Wickham","year":"2009","unstructured":"Wickham H (2009) ggplot2: Elegant graphics for data analysis. Springer-Verlag, New York"},{"key":"3679_CR14","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Rationale for the EUCAST clinical breakpoints (v 1.0). \nhttp:\/\/www.eucast.org\/documents\/rd\/"},{"key":"3679_CR15","unstructured":"GlaxoSmithKline (2013) Summary of product characteristics: Augmentin amoxicillin\/clavulanic acid 500 mg\/125 mg oral tablets. Zeist, Netherlands"},{"issue":"6","key":"3679_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1365-2125.2008.03292.x","volume":"66","author":"AE Muller","year":"2008","unstructured":"Muller AE, Dorr PJ, Mouton JW, De Jongh J, Oostvogel PM, Steegers EA et al (2008) The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. Br J Clin Pharmacol 66(6):866\u2013874. \nhttps:\/\/doi.org\/10.1111\/j.1365-2125.2008.03292.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3679_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1128\/AAC.17.2.199","volume":"17","author":"A Arancibia","year":"1980","unstructured":"Arancibia A, Guttmann J, Gonzalez C (1980) Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother 17(2):199\u2013202. \nhttps:\/\/doi.org\/10.1128\/AAC.17.2.199","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3679_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","volume":"22","author":"WA Craig","year":"1995","unstructured":"Craig WA (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22(2):89\u201396. \nhttps:\/\/doi.org\/10.1016\/0732-8893(95)00053-D","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"3679_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0924-8579(00)00285-5","volume":"16","author":"A Novelli","year":"2000","unstructured":"Novelli A, Fallani S, Cassetta MI, Conti S, Donn KH, Bosso JA et al (2000) Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics. Int J Antimicrob Agents 16(4):501\u2013505. \nhttps:\/\/doi.org\/10.1016\/S0924-8579(00)00285-5","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"3679_CR20","first-page":"414","volume":"89","author":"SM Singhvi","year":"1977","unstructured":"Singhvi SM, Heald AF, Gadebusch HH, Resnick ME, Difazio LT, Leitz MA (1977) Human serum protein binding of cephalosporin antibiotics in vitro. J Lab Clin Med 89(2):414\u2013420","journal-title":"J Lab Clin Med"},{"issue":"6","key":"3679_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/j.1552-4604.1976.tb02402.x","volume":"16","author":"DS Greene","year":"1976","unstructured":"Greene DS, Flanagan DR, Quintiliani R, Nightingale CH (1976) Pharmacokinetics of cephalexin: an evaluation of one and two compartment model pharmacokinetics. J Clin Pharmacol 16(6):257\u2013264. \nhttps:\/\/doi.org\/10.1002\/j.1552-4604.1976.tb02402.x","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"3679_CR22","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/jac\/dkr220","volume":"66","author":"D Khachman","year":"2011","unstructured":"Khachman D, Conil J, Georges B, Saivin S, Houin G, Toutain P et al (2011) Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. J Antimicrob Chemother 66(8):1798\u20131809. \nhttps:\/\/doi.org\/10.1093\/jac\/dkr220","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3679_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.37.5.1065","volume":"37","author":"A Forrest","year":"1993","unstructured":"Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ (1993) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37(5):1065\u20131072. \nhttps:\/\/doi.org\/10.1128\/AAC.37.5.1065","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3679_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1128\/AAC.30.3.444","volume":"30","author":"GL Drusano","year":"1986","unstructured":"Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J (1986) Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 30(3):444\u2013446. \nhttps:\/\/doi.org\/10.1128\/AAC.30.3.444","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"3679_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2165\/00003088-200241140-00005","volume":"41","author":"MD S\u00e1nchez Navarro","year":"2002","unstructured":"S\u00e1nchez Navarro MD, Coloma Milano C, Zarzuelo Casta\u00f1eda A, Sayalero Marinero ML, S\u00e1nchez-Navarro A (2002) Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. Clin Pharmacokinet 41(14):1213\u20131220. \nhttps:\/\/doi.org\/10.2165\/00003088-200241140-00005","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3679_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/j.1875-9114.1986.tb03458.x","volume":"39","author":"M LeBel","year":"1989","unstructured":"LeBel M, Barbeau G, Bergeron M, Roy D, Vall\u00e9e F (1989) Pharmacokinetics of ciprofloxacin in elderly patients. Arzneimittel-Forschung. 39(4):523\u2013527. \nhttps:\/\/doi.org\/10.1002\/j.1875-9114.1986.tb03458.x","journal-title":"Arzneimittel-Forschung."},{"key":"3679_CR27","doi-asserted-by":"publisher","unstructured":"Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG et al (2017) In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 61(6). \nhttps:\/\/doi.org\/10.1128\/AAC.00476-17","DOI":"10.1128\/AAC.00476-17"},{"issue":"4","key":"3679_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","volume":"53","author":"SS Patel","year":"1997","unstructured":"Patel SS, Balfour JA, Bryson HM (1997) Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 53(4):637\u2013656. \nhttps:\/\/doi.org\/10.2165\/00003495-199753040-00007","journal-title":"Drugs."},{"issue":"7","key":"3679_CR29","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/jac\/dkv067","volume":"70","author":"NJ Rhodes","year":"2015","unstructured":"Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N et al (2015) Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother 70(7):2068\u20132073. \nhttps:\/\/doi.org\/10.1093\/jac\/dkv067","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3679_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55(5):601\u2013607. \nhttps:\/\/doi.org\/10.1093\/jac\/dki079","journal-title":"J Antimicrob Chemother"},{"key":"3679_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1469-0691.2011.03752.x","volume":"18","author":"JW Mouton","year":"2012","unstructured":"Mouton JW, Brown DFJ, Apfalter P, Cant\u00f3n R, Giske CG, Ivanova M et al (2012) The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 18:3. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2011.03752.x","journal-title":"Clin Microbiol Infect"},{"key":"3679_CR32","unstructured":"Joint formulary committee. British National Formulary. BMJ Group and Pharmaceutical Press, London, UK. \nhttps:\/\/www.medicinescomplete.com"},{"issue":"7","key":"3679_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00228-008-0493-7","volume":"64","author":"K Ogungbenro","year":"2008","unstructured":"Ogungbenro K, Aarons L (2008) How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. Eur J Clin Pharmacol 64(7):705\u2013713. \nhttps:\/\/doi.org\/10.1007\/s00228-008-0493-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3679_CR34","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s10096-018-3371-y","volume":"37","author":"JWS Cattrall","year":"2018","unstructured":"Cattrall JWS, Robinson AV, Kirby A (2018) A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis 37(12):2285\u20132291. \nhttps:\/\/doi.org\/10.1007\/s10096-018-3371-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3679_CR35","doi-asserted-by":"publisher","unstructured":"Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC (2014) Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev (7):CD003772. \nhttps:\/\/doi.org\/10.1002\/14651858.CD003772.pub4","DOI":"10.1002\/14651858.CD003772.pub4"},{"issue":"5","key":"3679_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1179\/joc.2005.17.5.484","volume":"17","author":"GT Hansen","year":"2005","unstructured":"Hansen GT, Blondeau JM (2005) Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric gram-negative urinary tract infection pathogens. J Chemother 17(5):484\u2013492. \nhttps:\/\/doi.org\/10.1179\/joc.2005.17.5.484","journal-title":"J Chemother"},{"issue":"8","key":"3679_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijmm.2017.09.019","volume":"307","author":"A Pourbaix","year":"2017","unstructured":"Pourbaix A, Gu\u00e9rin F, Lastours V d, Chau F, Auzou M, Boulley E et al (2017) Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection. Int J Med Microbiol 307(8):452\u2013459. \nhttps:\/\/doi.org\/10.1016\/j.ijmm.2017.09.019","journal-title":"Int J Med Microbiol"},{"issue":"5","key":"3679_CR38","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc10441","volume":"15","author":"J Gon\u00e7alves-Pereira","year":"2011","unstructured":"Gon\u00e7alves-Pereira J, P\u00f3voa P (2011) Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams. Crit Care 15(5):R206. \nhttps:\/\/doi.org\/10.1186\/cc10441","journal-title":"Crit Care"},{"issue":"2","key":"3679_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1017\/S0950268813000988","volume":"142","author":"CS Horner","year":"2014","unstructured":"Horner CS, Abberley N, Denton M, Wilcox MH (2014) Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010\u20132012. Epidemiol Infect 142(2):399\u2013403. \nhttps:\/\/doi.org\/10.1017\/S0950268813000988","journal-title":"Epidemiol Infect"},{"issue":"12","key":"3679_CR40","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","volume":"283","author":"DA Talan","year":"2000","unstructured":"Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A et al (2000) Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. JAMA. 283(12):1583. \nhttps:\/\/doi.org\/10.1001\/jama.283.12.1583","journal-title":"JAMA."}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03679-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03679-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03679-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T23:15:56Z","timestamp":1599347756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03679-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03679-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"3 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Funding sources had no involvement in the conduct of the research or preparation of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}